Epizyme Has 'Aggressive' Plans For Accelerated Tazemetostat Approval

A year after losing its big pharma partner, epigenetic cancer therapy-focused Epizyme Inc. used its quarterly earnings call on March 9 to outline a four-step strategy for becoming a commercial company, expanding the potential uses for lead candidate tazemetostat (EPZ-6438, aka taz) and bringing at least three novel proprietary cancer candidates into clinical development by 2020.

A year after losing its big pharma partner, epigenetic cancer therapy-focused Epizyme Inc. used its quarterly earnings call on March 9 to outline a four-step strategy for becoming a commercial company, expanding the potential uses for lead candidate tazemetostat (EPZ-6438, aka taz) and bringing at least three novel proprietary cancer candidates into clinical development by 2020.

Central to this strategy is a plan to seek expedited approval of tazemetostat based on findings from Phase II studies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

More from Therapy Areas

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.